Opinion|Videos|June 6, 2024
Safety Profile: Adverse Events and Treatment Modifications in MARIPOSA-2
A comprehensive look at the safety data from the MARIPOSA-2 trial, including rates of adverse events, toxicities, and treatment modifications across the three regimens. Specific details are provided on adverse event types and grades by the treatment arm.
Advertisement
Episodes in this series
Advertisement
Related to this article
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Advertisement
Advertisement
Trending on CancerNetwork
1
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
2
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
3
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5